


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A compound of formula (1):



wherein:

- the dashed line joining A and C(R^a) is present and represents a bond and A is
- a -C(R^b)= group;
- R^a and R^b are each hydrogen;
- ~~R¹ is methyl, ethyl or trifluoromethyl;~~
- ~~R² is a hydrogen atom or an optionally substituted alkyl group;~~
- X is a -CH= group;
- Y is a -C(R^e)= group;
- R^e is hydrogen, -CN, -COR¹, -CO₂R¹, -CONR^{1a}R^{2a}, -S(O)₂NR^{1a}R^{2a}, -CONR^{1a}OR^{2a} or -C(O)N(R^{3a})NR^{1a}R^{2a};
- R¹ is methyl, ethyl or trifluoromethyl
- R^{1a} and R^{2a} are, independently, a hydrogen atom or methyl group, or together with the nitrogen atom to which they are attached, represent -(CH₂)₄- or -CH(CH₂OH)(CH₂)₃-;
- R^{3a} is a hydrogen atom or C₁₋₆alkyl group;
- L is a -CH₂-, -CH(CH₃)-, -C(O)- or -CH₂CH₂- group;
- n is zero;

~~Alk¹ is an optionally substituted aliphatic or heteroaliphatic chain;~~

L¹ is a covalent bond;

Cy¹ is phenyl, ~~methyl~~, methylphenyl, ~~methoxyphenyl~~, methoxyphenyl, thienyl or indolyl; and

Ar represents phenyl, pyridinyl, thienyl or benzothienyl, any of which groups may be optionally substituted by one or two substituents selected from halogen, cyano, C₁₋₆ alkyl, C₁₋₆ alkoxy and nitro;
or a pharmaceutically acceptable salt or N-oxide thereof.

2 – 6. (Canceled)

7. (Previously presented) A compound as claimed in claim 1 wherein Ar is a phenyl, fluorophenyl, difluorophenyl, chlorophenyl, dichlorophenyl, (chloro)(fluoro)phenyl, cyanophenyl, methylphenyl, (fluoro)(methyl)phenyl, methoxyphenyl, nitrophenyl, pyridinyl, chlorothienyl or benzothienyl group.

8. (Previously presented) A compound as claimed in claim 1 which is
1 -Benzyl-4-phenyl- 1,4-dihydro-5*H*-pyrrolo [3 ,2-*b*]pyridin-5 -one;
1 -(3-Chlorobenzyl)-4-phenyl- 1 ,4-dihydro-5*H*-pyrrolo[3 ,2-*b*]pyridin-5 -one;
1-(4-Fluorobenzyl)-4-phenyl-1,4-dihydro-5*H*-pyrrolo[3,2-*b*]pyridin-5-one;
1-(2,6-Dichlorobenzyl)-4-phenyl-1,4-dihydro-5*H*-pyrrolo[3,2-*b*]pyridin-5-one;
1-(3-Methoxybenzyl)-4-phenyl-1,4-dihydro-5*H*-pyrrolo[3,2-*b*]pyridin-5-one;
1-Benzyl-4-(4-methoxyphenyl)-1,4-dihydro-5*H*-pyrrolo[3,2-*b*]pyridin-5-one;
1-Benzoyl--4-phenyl-1,4-dihydro-5*H*-pyrrolo[3,2-*b*]pyridin-5-one;
4-[(5-Oxo-4-phenyl-4,5-dihydro-1*H*-pyrrolo[3,2-*b*]pyridin-1-yl)methyl]benzonitrile;
3-[5-Oxo-4-phenyl-4,5-dihydro-1*H*-pyrrolo[3,2-*b*]pyridin-1-yl)methyl]benzonitrile;
1-(2-Methylbenzyl)-4-phenyl-1,4-dihydro-5*H*-pyrrolo[3,2-*b*]pyridin-5-one;
1-(3-Methylbenzyl)-4-phenyl-1,4-dihydro-5*H*-pyrrolo[3,2-*b*]pyridin-5-one;
1-(4-Methylbenzyl)-4-phenyl-1,4-dihydro-5*H*-pyrrolo[3,2-*b*]pyridin-5-one;
1-(4-Chlorobenzyl)-4-phenyl-1,4-dihydro-5*H*-pyrrolo[3,2-*b*]pyridin-5-one;

1-(3,4-Dichlorobenzyl)-4-phenyl-1,4-dihydro-5*H*-pyrrolo[3,2-*b*]pyridin-5-one;
 1-(2,5-Dichlorobenzyl)-4-phenyl-1,4-dihydro-5*H*-pyrrolo[3,2-*b*]pyridin-5-one;
 1-(3,4-Difluorobenzyl)-4-phenyl-1,4-dihydro-5*H*-pyrrolo[3,2-*b*]pyridin-5-one;
 1-(2,4-Difluorobenzyl)-4-phenyl-1,4-dihydro-5*H*-pyrrolo[3,2-*b*]pyridin-5-one;
 1-(3-Chloro-4-fluorobenzyl)-4-phenyl-1,4-dihydro-5*H*-pyrrolo[3,2-*b*]pyridin-5-one;
 4-Phenyl-1-(pyridin-4-ylmethyl)-1,4-dihydro-5*H*-pyrrolo[3,2-*b*]pyridin-5-one;
 4-Phenyl-1-(pyridin-3-ylmethyl)-1,4-dihydro-5*H*-pyrrolo[3,2-*b*]pyridin-5-one;
 4-Phenyl-1-(1-phenylethyl)-1,4-dihydro-5*H*-pyrrolo[3,2-*b*]pyridin-5-one;
 1-(3-Chlorobenzyl)-4-phenyl-2-(pyrrolidin-1-ylsulfonyl)-1,4-dihydro-5*H*-pyrrolo[3,2-*b*]pyridin-5-one;
 Ethyl 1-benzyl-5-oxo-4-phenyl-4,5-dihydro-1*H*-pyrrolo[3,2-*b*]pyridine-2-carboxylate;
 Ethyl 1-(3-chloro-4-fluorobenzyl)-5-oxo-4-phenyl-4,5-dihydro-1*H*-pyrrolo[3,2-*b*]pyridine-2-carboxylate;
 Ethyl 1-(3-methylbenzyl)-5-oxo-4-phenyl-4,5-dihydro-1*H*-pyrrolo[3,2-*b*]pyridine-2-carboxylate;
 Ethyl 1-(3-chlorobenzyl)-5-oxo-4-phenyl-4,5-dihydro-1*H*-pyrrolo[3,2-*b*]pyridine-2-carboxylate;
 1-(3-Chloro-4-fluorobenzyl)-*N*-methoxy-*N*-methyl-5-oxo-4-phenyl-4,5-dihydro-1*H*-pyrrolo[3,2-*b*]pyridine-2-carboxamide;
N-Methoxy-*N*-methyl-1-(3-methylbenzyl)-5-oxo-4-phenyl-4,5-dihydro-1*H*-pyrrolo[3,2-*b*]pyridine-2-carboxamide;
 1-(3-Chlorobenzyl)-*N*-methoxy-*N*-methyl-5-oxo-4-phenyl-4,5-dihydro-1*H*-pyrrolo[3,2-*b*]pyridine-2-carboxamide;
 1-(3-Chloro-4-fluorobenzyl)-5-oxo-4-phenyl-4,5-dihydro-1*H*-pyrrolo[3,2-*b*]pyridine-2-carboxamide;
 1-(3-Methylbenzyl)-5-oxo-4-phenyl-4,5-dihydro-1*H*-pyrrolo[3,2-*b*]pyridine-2-carboxamide;
 1-(3-Chlorobenzyl)-5-oxo-4-phenyl-4,5-dihydro-1*H*-pyrrolo[3,2-*b*]pyridine-2-carboxamide;
 4-Phenyl-1-(2-phenylethyl)-1,4-dihydro-5*H*-pyrrolo[3,2-*b*]pyridin-5-one;

1-(3-Chlorobenzyl)-5-oxo-4-phenyl-4,5-dihydro-1*H*-pyrrolo[3,2-*b*]pyridine-2-carbonitrile;

1-(3 -Chlorobenzyl)-*N,N*-dimethyl-5 -oxo-4-phenyl-4,5 -dihydro-1*H*-pyrrolo[3,2-*b*]pyridine-2-carboxamide;

1-(3-Chlorobenzyl)-*N*-methyl-5-oxo-4-phenyl-4,5-dihydro-1*H*-pyrrolo[3,2-*b*]pyridine-2-carboxamide;

1-(3-Chlorobenzyl)-4-phenyl-2-(pyrrolidin-1-ylcarbonyl)-1 ,4-dihydro-5*H*-pyrrolo[3,2- *b*]pyridin-5-one;

1-(3-Chlorobenzyl)-5-oxo-4-phenyl-4,5-dihydro-1*H*-pyrrolo[3,2-*b*]pyridine-2-carbohydrazide;

Ethyl 1-(3-chlorobenzyl)-4-(1*H*-indol-5-yl)-5-oxo-4,5-dihydro-1*H*-pyrrolo[3,2-*b*]pyridine-2-carboxylate;

Ethyl 1-(3-chlorobenzyl)-5-oxo-4-(3-thienyl)-4,5-dihydro-1*H*-pyrrolo[3,2-*b*]pyridine-2-carboxylate;

1-(3-Chlorobenzyl)-4-(1*H*-indol-5-yl)-5-oxo-4,5-dihydro-1*H*-pyrrolo[3,2-*b*]pyridine-2-carboxamide;

Ethyl 1-(4-fluoro-3-methylbenzyl)-5-oxo-4-phenyl-4,5-dihydro-1*H*-pyrrolo[3,2-*b*]pyridine-2-carboxylate;

1-(3-Chlorobenzyl)-4-(3-thienyl)-1,4-dihydro-5*H*-pyrrolo[3,2-*b*]pyridin-5-one;

Ethyl 1-(3-chlorobenzyl)-4-(4-methylphenyl)-5-oxo-4,5-dihydro-1*H*-pyrrolo[3,2-*b*]pyridine-2-carboxylate;.

1-(2-Cyanobenzyl)-5-oxo-4-phenyl-4,5-dihydro-1*H*-pyrrolo[3,2-*b*]pyridine-2-carboxamide;

1-(4-Fluoro-3-methylbenzyl)-5-oxo-4-phenyl-4,5-dihydro-1*H*-pyrrolo[3,2-*b*]pyridine-2- carboxamide;

1-(3-Chlorobenzyl)-4-(4-methylphenyl)-5-oxo-4,5-dihydro-1*H*-pyrrolo[3,2-*b*]pyridine-2-carboxamide;

1-(3-Chlorobenzyl)-4-(4-methylphenyl)-5-oxo-4,5-dihydro-1*H*-pyrrolo[3,2-*b*]pyridine-2- carbohydrazide;

Ethyl 1-(3-chlorobenzyl)-4-(2-nitrophenyl)-5-oxo-4,5-dihydro-1*H*-pyrrolo[3,2-

b]pyridine-2-carboxylate;

1-(1,3-Benzothiazol-2-ylmethyl)-4-phenyl-1,4-dihydro-5*H*-pyrrolo[3,2-*b*]pyridin-5-one;

1[(5-Chloro-2-thienyl)methyl]-4-phenyl-1,4-dihydro-5*H*-pyrrolo[3,2-*b*]pyridin-5-one;

1-Benzyl-4-phenyl-3-(trifluoroacetyl)-1,4-dihydro-5*H*-pyrrolo[3,2-*b*]pyridin-5-one; or


2-{[(2*S*)-2-(Hydroxymethyl)pyrrolidin-1-yl] carbonyl} -1-(3-methylbenzyl)-4-phenyl-1,4-dihydro-5*H*-pyrrolo[3,2-*b*]pyridin-5-one.

9. (Currently Amended) A pharmaceutical composition comprising a compound as claimed in claim 1, or a pharmaceutically acceptable salt, ~~solvate, hydrate~~ or *N*-oxide thereof, in association with a pharmaceutically acceptable carrier.

10. (Canceled)

11. (Canceled)

12. (Currently Amended and Withdrawn) A method for inhibiting p38 kinase activity in a patient suffering from a disease or disorder in which p38 kinase activity plays a role, comprising administering to the patient a pharmaceutically effective amount of a compound of formula (1):



wherein:

the dashed line joining A and C(R^a) is present and represents a bond and A is a -C(R^b)= group;


R^a and R^b are each hydrogen;

~~R¹ is methyl, ethyl or trifluoromethyl;~~

~~R² is a hydrogen atom or an optionally substituted alkyl group;~~

X is a -CH= group;
 Y is a -C(R^e)= group;
 R^e is hydrogen, -CN, -COR¹, -CO₂R¹, -CONR^{1a}R^{2a}, -S(O)₂NR^{1a}R^{2a}, -CONR^{1a}OR^{2a} or -C(O)N(R^{3a})NR^{1a}R^{2a};
R¹ is methyl, ethyl or trifluoromethyl;
 R^{1a} and R^{2a} are, independently, a hydrogen atom or methyl group, or together with the nitrogen atom to which they are attached, represent -(CH₂)₄- or -CH(CH₂OH)(CH₂)₃-;
 R^{3a} is a hydrogen atom or C₁₋₆alkyl group;
 L is a -CH₂-, -CH(CH₃)-, -C(O)- or -CH₂CH₂- group;
 n is zero;
~~Alk⁺ is an optionally substituted aliphatic or heteroaliphatic chain;~~
 L¹ is a covalent bond;
 Cy¹ is phenyl, ~~methyl~~, methylphenyl, ~~methoxyphenyl~~, methoxyphenyl, thienyl or indolyl; and
 Ar represents phenyl, pyridinyl, thienyl or benzothienyl, any of which groups may be optionally substituted by one or two substituents selected from halogen, cyano, C₁₋₆ alkyl, C₁₋₆ alkoxy and nitro;
 or a pharmaceutically acceptable ~~prodrug~~, salt, or N-oxide thereof.

13. (Currently Amended and Withdrawn) A method for treating autoimmune diseases, inflammatory diseases, destructive-bone disorders, proliferative disorders, neurodegenerative disorders, viral diseases, allergies, infectious diseases, heart attacks, angiogenic disorders, reperfusion/ischemia in stroke, vascular hyperplasia, organ hypoxia, cardiac hypertrophy, thrombin-induced platelet aggregation, and conditions associated with prostaglandin endoperoxidase synthetase-2 (COX-2) comprising administering to a patient suffering from such a disease or disorder a pharmaceutically effective amount of a compound of formula (1):



wherein:

the dashed line joining A and C(R^a) is present and represents a bond and A is a -C(R^b)= group;

R^a and R^b are each hydrogen;

~~R¹ is methyl, ethyl or trifluoromethyl;~~

~~R² is a hydrogen atom or an optionally substituted alkyl group;~~

X is a -CH= group;

Y is a -C(R^c)= group;

R^c is hydrogen, -CN, -COR¹, -CO₂R¹, -CONR^{1a}R^{2a}, -S(O)₂NR^{1a}R^{2a}, -CONR^{1a}OR^{2a} or -C(O)N(R^{3a})NR^{1a}R^{2a};

R¹ is methyl, ethyl or trifluoromethyl;

R^{1a} and R^{2a} are, independently, a hydrogen atom or methyl group, or together with the nitrogen atom to which they are attached, represent -(CH₂)₄- or -CH(CH₂OH)(CH₂)₃;

R^{3a} is a hydrogen atom or C₁₋₆alkyl group;

L is a -CH₂-, -CH(CH₃)-, -C(O)- or -CH₂CH₂- group;

n is zero;

~~Alk¹ is an optionally substituted aliphatic or heteroaliphatic chain;~~

L¹ is a covalent bond;

Cy¹ is phenyl, ~~methyl~~, methylphenyl, ~~methoxyphenyl~~, methoxyphenyl, thienyl or indolyl; and

Ar represents phenyl, pyridinyl, thienyl or benzothienyl, any of which groups may be optionally substituted by one or two substituents selected from halogen, cyano, C₁₋₆ alkyl, C₁₋₆ alkoxy and nitro;

or a pharmaceutically acceptable ~~prodrug~~, salt, or N-oxide thereof.

14. (Withdrawn) The method of claim 13 wherein the autoimmune disease is rheumatoid arthritis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, multiple sclerosis, diabetes, glomerulonephritis, systemic lupus erythematosus, scleroderma, chronic thyroiditis, Grave's disease, hemolytic anemia, autoimmune gastritis, autoimmune neutropenia, thrombocytopenia, chronic active hepatitis, myasthenia gravis, atopic dermatitis, graft vs host disease or psoriasis.
15. (Withdrawn) The method of claim 13 wherein the inflammatory disease is asthma, allergies, respiratory distress syndrome, or acute or chronic pancreatitis.
16. (Withdrawn) The method of claim 13 wherein the destructive bone disorder is osteoporosis, osteoarthritis, or multiple myeloma-related bone disorder.
17. (Withdrawn) The method of claim 13 wherein the proliferative disorder is acute or chronic myelogenous leukemia, Kaposi's sarcoma, metastatic melanoma, or multiple myeloma.
18. (Withdrawn) The method of claim 13 wherein the neurodegenerative disorder is Parkinson's disease, Alzheimer's disease, cerebral ischemias, or neurodegenerative disease caused by traumatic injury.
19. (Withdrawn) The method of claim 13 wherein the viral disease is acute hepatitis A, hepatitis B, or hepatitis C infection; HIV infection; or CMV retinitis.
20. (Withdrawn) The method of claim 13 wherein the infections disease is septic shock, sepsis, or Shigellosis.
21. (Withdrawn) The method of claim 13 wherein the condition associated with prostaglandin endoperoxidase synthetase-2 (COX-2) is edema, analgesia, fever, neuromuscular pain, headache, dental pain, arthritis pain, or pain caused by cancer.